Botulinum Toxin (Dysport) to Prevent Radiation‐Induced Dysfunction of Salivary Glands in Head and Neck Cancer
Cancer Reports · 2026-05 · 9 (5)
DOI: 10.1002/cnr2.70576 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Reports, online erschienen am 19.05.2026. Verfasst von Farshid Farhan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Cancer Institute, Imam-Khomeini Hospital Complex (IKHC), Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Botulinum Toxins, Head and Neck Neoplasms, Radiation Injuries, Salivary Glands. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The main goal of this pilot trial was to investigate the efficacy of botulinum toxin (Dysport) injection before radiotherapy in preserving salivary gland secretion in patients with head and neck cancer.
Methods
Sixteen patients with head and neck cancer were enrolled, 9 received 50 IU Dysport, and 7 recieved NaCl (0.9%) into the submandibular glands before chemo‐radiotherapy. To investigate the salivary gland function, technetium pertechnetate salivary gland scintigraphy, as well as saliva accumulation and the University of Washington Quality of Life (UW‐QoL) Questionnaire were utilized “before” and “6 months after the end” of radiotherapy.
Results
Sixteen patients were randomized (9 botulinum toxin, 7 placebo). Baseline characteristics were comparable between groups. At 6 months post‐radiotherapy, basal saliva volume was higher in the botulinum toxin group (median 5.0 cc vs. 2.0 cc; p < 0.001) as was stimulated saliva volume (6.0 cc vs. 2.0 cc; p < 0.001). UW‐QoL scores were significantly lower, indicating better quality of life, in the botulinum toxin group (37.0 vs. 67.0; p < 0.001). Covariate‐adjusted analyses confirmed botulinum toxin as the only significant predictor of saliva preservation and improved QoL.
Conclusion
A single injection of botulinum toxin before radiotherapy preserves salivary gland function and improves quality of life. Based on these findings, we advocate for a multicenter Phase II trial to define the optimal dose–response relationship and determine the ideal timing for injection relative to the start of radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Oncology Department, Cancer Institute, Imam-Khomeini Hospital Complex (IKHC), Tehran University of Medical Sciences, Tehran, Iran.
- Radiation Oncology Research Center (RORC), Imam Khomeini Hospital Complex, Tehran, Iran.
- Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Otolaryngology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Otolaryngology, Amir-Alam Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Radiology Department, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Amirhossein Shahsavand, Reza Samiee, Mehrshad Abbasi, Fatemeh Jafari
Zitieren
APA
Farhan, F., Eyvaz-Zadeh, I., Forghani, S., Shahsavand, A., Samiee, R., Mansouri, S., Abbasi, M., Kazemian, A., Aghili, M., Jafari, M., Karimi, E., Esmati, E., & Jafari, F. (2026). Botulinum Toxin (Dysport) to Prevent Radiation‐Induced Dysfunction of Salivary Glands in Head and Neck Cancer. Cancer Reports, 9(5). https://doi.org/10.1002/cnr2.70576
Vancouver
Farhan F, Eyvaz-Zadeh I, Forghani S, Shahsavand A, Samiee R, Mansouri S, et al. Botulinum Toxin (Dysport) to Prevent Radiation‐Induced Dysfunction of Salivary Glands in Head and Neck Cancer. Cancer Reports. 2026;9(5). doi:10.1002/cnr2.70576
BibTeX
@article{Farhan2026,
author = {Farhan, Farshid and Eyvaz-Zadeh, Iraj and Forghani, Shayan and Shahsavand, Amirhossein and Samiee, Reza and Mansouri, Sepideh and Abbasi, Mehrshad and Kazemian, Ali and Aghili, Mahdi and Jafari, Mehrdad and Karimi, Ebrahim and Esmati, Ebrahim and Jafari, Fatemeh},
title = {Botulinum Toxin (Dysport) to Prevent Radiation‐Induced Dysfunction of Salivary Glands in Head and Neck Cancer},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/cnr2.70576}
}
EUVIMED